AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.984
-0.056 (-5.35%)
Apr 28, 2026, 4:00 PM EDT - Market closed

AEON Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Selling, General & Admin
12.2113.6419.7913.6811.15
Upgrade
Research & Development
4.0914.1833.0534.7525.73
Upgrade
Operating Expenses
16.327.8252.8448.4336.88
Upgrade
Operating Income
-16.3-27.82-52.84-48.43-36.88
Upgrade
Other Non Operating Income (Expenses)
-3.51-34.29-17.190.29-0.14
Upgrade
EBT Excluding Unusual Items
-19.81-62.12-70.02-48.14-37.02
Upgrade
Legal Settlements
-----28.97
Upgrade
Other Unusual Items
-19.41104.1233.39-4.4210.35
Upgrade
Pretax Income
-39.2242.01-384.63-52.56-55.64
Upgrade
Earnings From Continuing Operations
-39.2242.01-384.63-52.56-55.64
Upgrade
Net Income
-39.2242.01-384.63-52.56-55.64
Upgrade
Net Income to Common
-39.2242.01-384.63-52.56-55.64
Upgrade
Shares Outstanding (Basic)
1017722
Upgrade
Shares Outstanding (Diluted)
1017722
Upgrade
Shares Change (YoY)
1622.66%-99.25%3896.62%9.98%1813.85%
Upgrade
EPS (Basic)
-3.9577.74-4.99-27.25-31.73
Upgrade
EPS (Diluted)
-3.9572.93-4.99-27.25-31.73
Upgrade
Free Cash Flow
-17.31-20.29-47.83-35.89-28.6
Upgrade
Free Cash Flow Per Share
-1.75-35.23-0.62-18.61-16.31
Upgrade
EBITDA
-16.22-27.73-52.74-48.36-36.88
Upgrade
D&A For EBITDA
0.080.10.10.070
Upgrade
EBIT
-16.3-27.82-52.84-48.43-36.88
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.